International Stem Cell CORP (ISCO) stock
Close on Oct 19, 2026Market cap $2.27MP/E –Yield –
International Stem Cell CORP grew revenue 3.4% to $9.51M over the twelve months to Jun 30, 2026. Free cash flow was $333.00K, up 851.4% from a year earlier. At the latest close the market valued the company at $2.27M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.27M
- P/E ratio
- –
- Price to sales
- 0.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 14.70%
Fundamentals
- Revenue
- $9.51M
- Net income
- -$582.00K
- EPS, diluted
- -$0.08
- Free cash flow
- $333.00K
- Book value per share
- -$0.53
- Diluted shares
- 8M
Trading
- Previous close
- $0.28
- Open
- $0.27
- Day's range
- $0.27 – $0.29
- Volume
- 26,456
- Average volume (20 days)
- 12,473
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ISCO | S&P 500 | Difference | ISCO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.2% | +0.6% | −13.8 pts | ||
| 3 months | +57.2% | +3.4% | +53.8 pts | ||
| Year to date | +102.1% | +13.3% | +88.9 pts | ||
| 1 year | +88.7% | +16.6% | +72.1 pts | ||
| 3 years | +117.7% | +86.4% | +31.3 pts | +29.6% | +23.1% |
| 5 years | -45.6% | +81.9% | −127.4 pts | -11.5% | +12.7% |
| 10 years | -84.3% | +318.9% | −403.1 pts | -16.9% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
About International Stem Cell
Pharmaceutical Preparations
International Stem Cell Corporation is a clinical-stage biotechnology company that focuses on developing therapeutic and biomedical products using human parthenogenetic stem cells. The company develops neural stem cells for central nervous system disorders such as Parkinson's disease, traumatic brain injury, and stroke. In addition to clinical research, it operates two commercial business units: research products and anti-aging skincare. Its research subsidiary manufactures human cell culture products, primary cells, stem cells, and specialized media for pharmaceutical, academic, and government research scientists. Its skincare subsidiary offers anti-aging cosmetic products to consumers and professionals, including dermatologists and plastic surgeons.
Company profile, executives and historyInternational Stem Cell stock: common questions
What is International Stem Cell's stock price?
ISCO closed at $0.28 on Oct 19, 2026, up 0.89% on the day.
What is International Stem Cell's market cap?
International Stem Cell was worth $2.27M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ISCO's P/E ratio?
International Stem Cell lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.08), so it has no meaningful P/E ratio.
How much revenue does International Stem Cell make?
International Stem Cell reported revenue of $9.51M for the twelve months to Jun 30, 2026, up 3.4% from a year earlier.
Does International Stem Cell pay a dividend?
No. International Stem Cell has not paid a cash dividend over the last twelve months.
How has ISCO stock performed over the past year?
Including dividends, ISCO returned +88.7% over the past year, against +16.6% for the S&P 500.
Who are International Stem Cell's competitors?
Companies most similar to International Stem Cell by business, industry and size include APLM, CELU, PRAX, CAPR, LCTX.
See a number that looks wrong?